The growth inhibition of hepatoma by gene transfer of antisense vascular endothelial growth factor

Journal of Gene Medicine

Volumn 2, Issue 4, 2000, Pages 289-296

  Kang, Mi Ae ^a   Kim, Kye Young ^a   Seol, Ji Yeon ^a   Kim, Kyu Chan ^a   Nam, Myeong Jin ^a  

^a Korea National Institute of Health   (South Korea)

Author keywords

Antisense; Gene therapy; Hepatoma; VEGF

Indexed keywords

BOVINAE; MAMMALIA; MUS MUSCULUS;

COMPLEMENTARY DNA; ENDOTHELIAL CELL GROWTH FACTOR; LIPOSOME; LYMPHOKINE; VASCULOTROPIN; VASCULOTROPIN A;

ANIMAL; ARTICLE; BIOSYNTHESIS; CAPILLARY; CATTLE; CELL CULTURE; CELL DIVISION; CYTOLOGY; DRUG ANTAGONISM; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIUM;

ANIMALS; CAPILLARIES; CARCINOMA, HEPATOCELLULAR; CATTLE; CELL DIVISION; CELLS, CULTURED; DNA, ANTISENSE; DNA, COMPLEMENTARY; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; LIPOSOMES; LIVER NEOPLASMS; LYMPHOKINES; NEOVASCULARIZATION, PATHOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0034220181     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1521-2254(200007/08)2:4<289::aid-jgm116>3.0.co;2-1     Document Type: Article

References (31)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
2. Klagsbrun M, D'Amore PA. Regulators of angiogenesis. Annu Rev Physiol 1991; 53: 217-239.
3. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6.
4. Folkman J, Hochberg M. Self-regulation of growth in three dimensions. J Exp Med 1973; 138: 745-753.
5. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD, Wiegand SJ. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999; 284: 1994-1998.
6. Folkman J, D'Amore PA. Blood vessel formation: what is its molecular basis? Cell 1996; 87: 1153-1155.
7. Folkman J. Angiogenesis inhibitors generated by tumors. Mol Med 1995; 1: 120-122.
8. Folkman J. The influence of angiogenesis research on management of patients with breast cancer. Breast Cancer Res Treat 1995; 36: 109-118.
9. Gross JL, Herblin WF, Dusak BA, Czerniak P, Diamond MD, Sun T, Eidsvoog K. Effects of modulation of basic fibroblast growth factor on tumor growth in vivo. J Natl Cancer Inst 1993; 85: 121-131.
10. Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, Heine UI. Transforming growth factor type β: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci U S A 1986; 83: 4167-4171.
11. Frater-Schroder M, Risau W, Hallmann R, Gautschi P, Bohlen P. Tumor necrosis factor type a: a potent inhibitor of endothelial cell growth in vitro is angiogenetic in vivo. Proc Natl Acad Sci U S A 1987; 84: 5277-5281.
12. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, Elner SG. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992; 258: 1798-1801.
13. Fett JW, Strydom DJ, Lobb RR, Alderman EM, Bethune JL, Riordan JF, Vallee BL. Isolation and characterization of angiogenin, an angiogenetic protein from human carcinoma cells. Biochem 1985; 24: 5480-5486.
14. Plouet J, Schilling J, Gospodarowicz D. Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT20 cells. EMBO J 1989; 8: 3801-3807.
15. Dvorak HF, Sioussat TM, Brown LF, Berse B, Nagy JA, Sotrel A, Manseau EJ. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. J Exp Med 1991; 174: 1275-1278.
16. de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT. The fms-like tyrosin kinase, a receptor for vascular endothelial growth factor. Science 1992; 255: 989-991.
17. Millauer B, Wizigmann-Voos S, Schnurch H, Martinez R, Moiler NPH, Risau W, Ullrich A. High affinity VEGF binding and developmental expression suggest FLK-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993; 72: 835-846.
18. Abraham JA, Whang JL, Tumoto A, Mergia A, Friedman J, Gospodarowicz D, Fiddes JC. Human basic fibroblast growth factor: nucleotide sequence and genomic organization. EMBO J 1986; 5: 2523-2528.
19. Shibuya M. Role of VEGF-flt receptor system in normal and tumor angiogenesis. Adv Cancer Res 1995; 67: 281-316.
20. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxiainitiated angiogenesis. Nature 1992; 359: 843-845.
21. Saleh M, Stacker SA, Wilks AF. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res 1996; 56: 393-401.
22. Im SA, Gomez-Manzano C, Fueyo J, Liu TJ, Ke LD, Kim JS, Lee HY, Steck PA, Kyritsis AP, Yung WK. Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo. Cancer Res 1999; 59: 895-900.
23. Cheng SY, Huang HJ, Nagane M, Ji XD, Wang D, Shih CC, Arap W, Huang CM, Cavenee WK. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci U S A 1996; 93: 8502-8507.
24. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-364.
25. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989; 161: 851-858.
26. Agrawal S. Antisense oligonucleotides as antiviral agents. Trends Biotechnol 1992; 10: 152-158.
27. Wickstrom E. Strategies for administering targeted therapeutic oligodeoxynucleotides. Trends Biotechnol 1992; 10: 281-287.
28. Ma DD, Doan TL. Antisense oligonucletide therapies: are they the 'magic bullets'? Ann Intern Med 1994; 120: 161-163.
29. Hug P, Sleight RG. Liposomes for the transformation of eukaryotic cells. Biochim Biophys Acta 1991; 1097: 1-17.
30. Aoki K, Yoshida T, Sugimura T, Terada M. Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity. Cancer Res 1995; 55: 3810-3816.
31. Bellamy WT, Richter L, Frutiger Y, Grogan TM. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 1999; 59: 728-733.